US Patent Issued to BeOne Medicines I on Jan. 13 for "Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand methods of use" (Chinese Inventors)

ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,521,440, issued on Jan. 13, was assigned to BeOne Medicines I GmbH (Basel, Switzerland).

"Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand methods of use" was invented by Changxin Huo (Beijing), Hexiang Wang (Beijing), Ruipeng Qi (Beijing), Zhiwei Wang (Beijing) and Huaqing Liu (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof."

The patent was f...